



Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients with Frequently Relapsing or Steroid-dependent Nephrotic Syndrome: a Prospective, Randomized, Multicenter, Open-label, and Parallel-arm Study on Efficacy and Safety (the STAMP study)

# **Statistical Analysis Plan**

NCT No.:	NCT04048161
Protocol No.:	NSTAMF02
Protocol version No.:	V 2.1
Protocol version date:	June 10, 2019
0	Hangzhou Zhongmeihuadong
<b>C</b>	
Sponsor:	Pharmaceutical Co., Ltd.
Sponsor: Statistical analysis:	Pharmaceutical Co., Ltd.
	Pharmaceutical Co., Ltd. Peking University Clinical

#### **Confidentiality Statement**

This document is intended for use only by the investigators involved in this study, their medical institutions, ethics committees or institutional review committees, and other authorized staff. May not be used, divulged, published or otherwise disclosed without the written permission of the sponsor.



# Signature Page

Study title	Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric
	Patients with Frequently Relapsing or Steroid-dependent
	Nephrotic Syndrome: a Prospective, Randomized,
	Multicenter, Open-label, and Parallel-arm Study on Efficacy
	and Safety
Statistical analysis issued by:	Peking University Clinical Research Institute
I have read this plan and confirm	that it accurately describes the implementation plan for the
statistical analysis of the study.	
SAP prepared by (signature):	
Date:	
Sponsor:	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.
Sponsor (signature):	
Date:	



# **Revision History**

Version No.	Amended on	Revised by
V 0.3	December 5, 2019	
V 0.4	March 24, 2023	
V 0.5	May 19, 2023	
V 0.6	July 3, 2023	
V 0.7	July 21, 2023	
V 0.8	July 24, 2023	
V 1.0	July 25, 2023	



## CONTENTS

1. Abbreviations	
2. Study title	12
3. Study objectives and endpoints	12
3.1 To evaluate the efficacy of the test drugs on the frequently relapsing or steroid-o	lependent nephrotic syndrome in
pediatric patients	
3.2 To assess the safety outcomes of test drugs	
4. Study design	13
4.1. Design overview	
4.2. Design principle and case allocation	
4.2.1 Difference analysis	
4.2.2 Determination of the number of cases	
4.3. Research plan	
4.4. Clinical trial flow chart	
4.5. Selection of cases	21
4.5.1. Inclusion criteria	21
4.5.2. Exclusion criteria	21
4.5.3. Elimination criteria	
4.5.4. Withdrawal criteria	
4.5.5. Drop-out and treament	23
4.5.5.1 Definition of drop-out	
4.5.5.2 Treatment of drop-out cases	
4.5.6. Relevant definitions in inclusion and exclusion criteria	
5. Test drugs and their allocation	24
5.1. Drug name and specifications	24
5.2. Administration method, dose, route and course of treatment	25
5.2.1. Initial administration protocol	25
5.2.2. Treatment of relapses	
5.2.3. Dose adjustment of tacrolimus (FK506)	
5.2.4. Dose adjustment of mycophenolate mofetil (MMF)	26
5.3. concomitant medication	
5.4. MEDICATION ADHERENCE	
6. Evaluation of efficacy and safety	
6.1. Primary efficacy outcomes	
6.2. Efficacy evaluation	
6.2.1. Primary observation outcomes: 1-year relapse-free survival	
6.2.2. Secondary observation outcomes:	



6.2.3. Efficacy criteria	
6.2.4. Relapse criteria	
6.3. Safety evaluation	29
7. Statistical analysis	29
7.1. Analysis data set	29
7.2. General considerations of date analyses	29
7.2.1. General Statistical methods	
7.2.2. Statistical inference method	
8. Data handling conventions	
8.1. Content of Statistical analysis	
8.1.1. Basic value equilibrium analysis	
8.1.2. Effectiveness analysis	
8.1.3. Primary efficacy analysis	
8.1.4. Secondary efficacy analysis	
8.1.5. Other analysis	
8.1.6. Safety analysis	
9. Statistical analysis results	
9.1. Research overview	
Table 1. Distribution of subjects at each site (All enrolled subjects)	34
Table 2. Distribution of subjects at each site	35
Table 3. Trial completion and distribution of analysis data set (All enrolled subjects)	
9.2. Demographic characteristics (FAS)	
Table 4. Baseline demographics	
Table 5. Baseline vital signs	
Table 6. Family history and personal history	
Table 7. History of other diseases, concomitant medications and nephrotic syndrome	42
Table 8. Visual palpation of physical examination Items	43
Table 9. Diagnostic consultation of physical examination Items	45
9.3. Baseline examinations (FAS)	47
Table 10. DNA/antibody tests	
Table 11. Hepatitis virus	48
Table 12. Examination of mycobacterium tuberculosis and fungi	49
Table 13. Urine test	49
Table 14. Glomerular filtration rate	
Table 15. Retained biological samples of blood and urine	50
Table 16. Chest X-ray	51
Table 17. ECG examinations	51
Table 18. Primary diagnosis	51
9.4. Efficacy analysis (FAS/PPS)	52
9.4.1. Primary efficacy indicators: 1-year relapse-free survival rate	52



Table 19. 1-year relapse-free survival analysis	
Figure 1. 1-year relapse-free survival analysis chart (FAS)	53
Figure 2. 1-year relapse-free survival analysis chart (PPS)	53
9.4.2. Secondary efficacy indicators	54
9.4.2.1. The first relapse survival analysis after enrollment	54
Table 20. The time of the first relapse after enrollment	54
Table 21. The first relapse survival analysis after enrollment	54
9.4.2.2. 6-month relapse-free survival analysis after enrollment	55
Table 22. 6-month relapse-free survival analysis after enrollment	55
Figure 3. 6-month relapse-free survival analysis chart (FAS)	55
Figure 4. 6-month relapse-free survival analysis chart (PPS)	55
9.4.2.3. Serum renal function	
Table 23. Changes in eGFR relative to baseline at each visit	
Figure 5. Quantitative variables of eGFR at each visit	60
Table 24. Change in Scr from baseline at each visit	60
Figure 6. Quantitative variables of Scr at each visit	60
Table 25. Change in serum uric acid from baseline at each visit	60
Figure 7. Quantitative variables of serum uric acid at each visit	61
Table 26. Change in blood urea nitrogen from baseline at each visit	61
Figure 8. Quantitative variables of blood urea nitrogen at each visit	61
Table 27. Change in serum cystatin C from baseline at each visit	61
Figure 9. Quantitative variables of serum cystatin C at each visit	61
9.4.2.4. Cumulative steroid dosage	61
Table 28. Total amount of steroids taken during the study	61
Table 29. Total amount of steroids taken during 6 months after enrollment	61
9.4.2.5. Vital signs	62
Table 30. Change in systolic blood pressure from baseline at each visit	62
Table 31. Change in diastolic blood pressure from baseline at each visit	62
Table 32. Change in height from baseline at each visit	62
Table 33. Change in weight from baseline at each visit	62
Table 34. Height percentile	62
9.4.2.6. Blood lipid	63
Table 35. Change in triglyceride from baseline at each visit	63
Table 36. Change in total cholesterol from baseline at each visit	63
9.4.2.7. Haemoglobin and albumin (ALB)	63
Table 37. Change in haemoglobin from baseline at each visit	63
Table 38. Change in ALB from baseline at each visit	63
9.4.2.8. Urine test	63
Table 39. Change in 24hr urine protein (>3 years old) from baseline at each visit	63
Table 40. Change in urine protein/creatinine (morning urine) from baseline at each visit	
9.4.2.9. Serum liver function and fasting blood glucose	63
Table 41. Change in glutamyl transpeptidase (GT) from baseline at each visit	63



Table 42. Change in alanine aminotransferase (ALT) from baseline at each visit	63
Table 43. Change in aspartate aminotransferase (AST) from baseline at each visit	63
Table 44. Change in lactate dehydrogenase from baseline at each visit	63
Table 45. Change in total bilirubin from baseline at each visit	63
Table 46. Change in direct bilirubin from baseline at each visit	63
Table 47. Change in alkaline phosphatase from baseline at each visit	63
Table 48. Change in total protein from baseline at each visit	63
Table 49. Change in globulin from baseline at each visit	64
Table 50. Change in fasting blood glucosefrom baseline at each visit	64
9.4.2.10. Blood routine examination	64
Table 51. Change in leukocyte count (WBC) from baseline at each visit	64
Table 52. Change in erythrocyte count (RBC) from baseline at each visit	64
Table 53. Change in platelet count (PLT) from baseline at each visit	64
Table 54. Change in lymphocyte percentage (LY) from baseline at each visit	64
9.4.2.11. Urine routine examination	64
Table 55. Change in leukocyte from baseline at each visit	64
Table 56. Change in erythrocyte from baseline at each visit	64
Table 57. Change in pH from baseline at each visit	64
Table 58. Change in urine protein from baseline at each visit	64
9.4.2.12. Plasma concentration	64
Table 59. Change in tacrolimus concentration in plasma from baseline at each visit	64
Table 60. Change in mycophenolic acid concentration in plasma from baseline at each visit	64
9.4.3. Disease remission	64
Table 61. Disease remission at each visit	64
9.5. Safety analysis (SS)	65
9.5.1. Adverse event (AE)	65
Table 62. Between-group comparison of AE	65
Table 63. characteristics of AE in each group	65
Table 64. Between-group comparison of SAE	66
Table 65. Summary of AE base on SOC and PT coding	66
Table 66. Summary of adverse reactions base on SOC and PT coding	67
9.5.2. Vital signs	68
Table 67. Change in heart rate from baseline at each visit	68
Table 68. Change in respiratory rate from baseline at each visit	72
9.5.3. Blood routine examination	72
Table 69. Summary of blood routine examination-Leukocyte count (WBC)	72
Table 70. Summary of blood routine examination-Lymphocyte percentage (LY)	73
Table 71. Shift-table of blood routine examination results before and after treatment-Leukocyte count (WBC)	73
Table 72. Shift-table of blood routine examination results before and after treatment-Erythrocyte count (RBC)	74
Table 73. Shift-table of blood routine examination results before and after treatment-Haemoglobin (Hb)	74
Table 74. Shift-table of blood routine examination results before and after treatment-Platelet count (PLT)	74
Table 75. Shift-table of blood routine examination results before and after treatment-Lymphocyte percentage (LY)	74



9.5.4. Urine routine examination	74
Table 76. Shift-table of urine routine examination results before and after treatment-Leukocyte	74
Table 77. Shift-table of urine routine examination results before and after treatment-Erythrocyte	74
Table 78. Shift-table of urine routine examination results before and after treatment-pH	74
Table 79. Shift-table of urine routine examination results before and after treatment-Urine protein	74
Table 80. Shift-table of urine routine examination results before and after treatment-Color	74
Table 81. Shift-table of urine routine examination results before and after treatment-Definition	74
9.5.5. Serum biochemistry	75
Table 82. Shift-table of serum biochemistry results before and after treatment-Glutamyl transpeptidase (GT)	75
Table 83. Shift-table of serum biochemistry results before and after treatment-Alanine aminotransferase (ALT)	75
Table 84. Shift-table of serum biochemistry results before and after treatment-Aspartate aminotransferase (AST)	75
Table 85. Shift-table of serum biochemistry results before and after treatment-Lactate dehydrogenase	75
Table 86. Shift-table of serum biochemistry results before and after treatment-Total bilirubin	75
Table 87. Shift-table of serum biochemistry results before and after treatment-Direct bilirubin	75
Table 88. Shift-table of serum biochemistry results before and after treatment-Alkaline phosphatase	75
Table 89. Shift-table of serum biochemistry results before and after treatment-Scr	75
Table 90. Shift-table of serum biochemistry results before and after treatment-Uric acid	75
Table 91. Shift-table of serum biochemistry results before and after treatment-Blood urea nitrogen	75
Table 92. Shift-table of serum biochemistry results before and after treatment-Cystatin C	75
Table 93. Shift-table of serum biochemistry results before and after treatment-Fasting blood glucose	75
Table 94. Shift-table of serum biochemistry results before and after treatment-Total cholesterol	75
Table 95. Shift-table of serum biochemistry results before and after treatment-Triglyceride	75
Table 96. Shift-table of serum biochemistry results before and after treatment-Total protein	
Table 97. Shift-table of serum biochemistry results before and after treatment-Albumin	75
Table 98. Shift-table of serum biochemistry results before and after treatment-Globulin	75
9.5.6. DNA/antibody test	75
Table 99. Shift-table of DNA/antibody test results before and after treatment-Blood EBV-DNA	75
Table 100. Shift-table of DNA/antibody test results before and after treatment-IgM	
Table 101. Shift-table of DNA/antibody test results before and after treatment-IgG	75
9.5.7. Urine test	75
Table 102. Shift-table of urine test results before and after treatment-24hr urine protein (>3 years old)	75
Table 103. Shift-table of urine test results before and after treatment-Urine protein/creatinine	
9.5.8. Glomerular filtration rate	
Table 104. Shift-table of eGFR results before and after treatment-eGFR	
9.5.9. Chest X-ray	
Table 105. Shift-table of chest X-ray results before and after treatment	
9.5.10. ECG	
Table 106. Shift-table of ECG examination results before and after treatment	
9.5.11. Concomitant medication and medication adherence	
Table 107. Concomitant medication	
Table 108. Medication adherence	
ttachments	



Table 109. List of subjects drop-out (All randomized subjects)	. 78
Table 110. List of subjects exclusions (All randomized subjects)	. 78
Table 111. List of protocol deviations (All randomize subjects)	. 78
Table 112. List of demographic characteristics (FAS)	. 78
Table 113. List of family history and personal history (FAS)	. 78
Table 114. List of history of other diseases and concomitant medications (FAS)	. 79
Table 115. List of history of nephrotic syndrome (FAS)	79
Table 116. List of treatment history for nephrotic syndrome (FAS)	. 79
Table 117. List of disease relapse (urine protein) situations (FAS)	79
Table 118. List of primary efficacy indicator (1-year relapse-free) situations (FAS/PPS)	. 79
Table 119. List of secondary efficacy indicator (first relapse after enrollment) situations (FAS/PPS)	80
Table 120. List of secondary efficacy indicator (6-month relapse-free) situations (FAS/PPS)	. 80
Table 121. List of blood routine examination results that were normal before treatment and abnormal after treatment (SS	5)80
Table 122. List of urine routine examination results that were normal before treatment and abnormal after treatment (SS)	) 80
Table 123. List of serum biochemistry results that were normal before treatment and abnormal after treatment (SS)	80
Table 124. List of urine test results that were normal before treatment and abnormal after treatment (SS)	. 81
Table 125. List of eGFR results that were normal before treatment and abnormal after treatment (SS)	81
Table 126. List of chest X-ray results that were normal before treatment and abnormal after treatment (SS)	81
Table 127. List of ECG examination results that were normal before treatment and abnormal after treatment (SS)	. 81
Table 128. List of AE (SS)	. 82
Table 129. List of AE-continued (SS)	. 82
Table 130. List of SAE (SS)	82
Table 131. List of SAE-continued (SS)	
Table 132. List of concomitant medication (SS)	83



### 1. Abbreviations

Abbreviations	Description
ALT	Alanine aminotransferase
ALB	Albumin
AUC	Area under curve
ACEi	Angiotensin converting enzyme inhibitor
ARB	Angiotensin II receptor blocker
AE	Adverse event
ANCOVA	Analysis of covariance
BID	Bis in die
CMV	Cytomegalovirus
CsA	Cyclosporin A
CR	Complete remission
CSR	Clinical Study Report
CRF	Case Report Form
СМН	Cochran's and Mantel-Haenszel
DAE	Drug adverse event
EB	Epstein-Barr
EBV-DNA	Epstein-Barr virus deoxyribonucleic acid
eGFR	Glomerular filtration rate
eCRF	Electronic Case Report Form
FAS	Full analysis set
FR	Frequent relapse
FDA	Food and Drug Administration
FK506	Tacrolimus
FK-BP-12	Tacrolimus binding protein-12
FK-BP-52	Tacrolimus binding protein-52



FK506-FKBP	Tacrolimus - tacrolimus binding protein
FRNS	Frequently relapsing nephrotic syndrome
GCP	Good Clinical Practice
g	Gram
GTP	Guanine nucleotide
HBV	Hepatitis B virus
HbsAg	Hepatitis B surface antigen
HbeAg	Hepatitis B E antigen
HbcAb	Hepatitis B core antigen
HCV	Hepatitis C virus
hr	Hour
ITT	Intentionality
LSMEAN	Least squares mean
LC-MS	Liquid chromatography-mass spectrometry
MMF	Mycophenolate mofetil
MPA	Mycophenolic acid
MPA-d3	Mycophenolic acid-d3
MPA-AUC	Mycophenolic acid - Area under curve
MI	Myocardial infarction
mg	Milligram
NR	No remission
РР	Per-protocol
PR	Partial remission
PML	Progressive multifocal leukoencephalopathy
PRCA	Pure red cell aplasia
PPS	Per-protocol set
SAS 9.4	STATISTICAL ANALYSIS SYSTEM Version 9.4
SD	Steroid-dependent



SDNS	Steroid-dependent nephrotic syndrome
SRNS	Steroid-resistant nephrotic syndrome
SCV	Site close-out visit
SAE	Serious adverse event
SOP	Standard Operation Procedures
SS	Safety set
Scr	Serum creatinine
TBiL	Total bilirubin
TIMP-1	Tissue inhibitor of metalloproteinase-1
TIA	Transient ischemic attack
WHO	World Health Organization
WBDC	Web-based data collection
α	Inspection level
β	Power of test
δ	Cut-off value

#### 2. Study title

Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients with Frequently Relapsing or Steroid-dependent Nephrotic Syndrome: a Prospective, Randomized, Multicenter, Open-label, and Parallel-arm Study on Efficacy and Safety

#### 3. Study objectives and endpoints

3.1 To evaluate the efficacy of the test drugs on the frequently relapsing or steroid-dependent nephrotic syndrome in pediatric patients

**Efficacy outcomes:** 

Primary observation outcomes: 1-year relapse-free survival

Secondary observation outcomes: Renal function; cumulative steroid dosage; blood pressure;



height; weight; blood lipids; hemoglobin; serum albumin; urinary protein/creatinine (morning urine); 24hr urinary protein quantification (applicable to subjects > 3 years old); frequency of relapses; the time of the first relapse after enrollment; relapse-free survival in the first six months after enrollment; adverse reactions;

#### 3.2 To assess the safety outcomes of test drugs

Changes of vital signs (respiration and heart rate), routine blood and urine tests, liver function, renal function, blood glucose, ECG, chest X-ray, and observation of clinically reported adverse events and adverse reactions.

#### 4. Study design

#### 4.1. Design overview

This trial is a prospective, randomized, multicenter, open-label, parallel-arm clinical study, using the Logrank method to compare the difference of 1-year relapse free survival between the two groups. Enrollment was completed by 12 sites using competitive enrollment. The whole observation period is 1 year for this trial. Eligible patients who sign the informed consent form will be randomly divided into FK506 Group or MMF Group at the ratio of 1:1. Both groups follow the "clinical trial flow chart" in operation.

#### 4.2. Design principle and case allocation

#### 4.2.1 Difference analysis

In this research, Logrank method is used to compare the difference of 1-year relapse-free survival between the two groups.

Eligible patients will be randomly divided into FK506 Group or MMF Group at the ratio of 1:1. The random codes are generated by the computer and the random envelopes are made according to these random codes. Grouping information is attached in each envelope. Each code is provided with a corresponding random envelope, and the random numbers are given to the subjects from small to large according to the time sequence when the subjects meet the inclusion criteria. The




corresponding random envelopes can only be opened when grouping. Any random number falling off midway after use cannot be used again.

#### 4.2.2 Determination of the number of cases

It is estimated that 1-year relapse-free survival is 0.56 in MMF Group, and 0.70 in FK506 Group. The enrollment time of this research is expected to be 2 years, and the total time of this research is 3 years, with a test level  $\alpha = 0.05$ , and a power of test 1-  $\beta = 80\%$ . It is estimated to have 114 patients in MMF group and 115 patients in FK506 group, with a total of 229 patients. With the consideration of 15% loss of follow-up, a total of 270 patients are needed, including 135 patients in each group.



#### 4.3. Research plan





#### 4.4. Clinical trial flow chart

## **Clinical trial flow chart**

Items	Screening and enrollment period		Treatment and follow-up period								
	Screen	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	
	(V0)	(V1)	(V2)	(V3)	(V4)	(V5)	(V6)	(V7)	(V8)	(V9)	
Follow-up week	Day -30 - 0	Included	Day 7	Day 28	Day 56	Day 112	Day 168	Day 224	Day 280	Day 364	
Sign the informed consent gorm	$\checkmark$										
Inclusion/exclusion criteria		$\checkmark$									



Stop the original immunosuppressants after 2 weeks	\$	\$								
Randomized										
General data										
Medical history (course of disease, frequency of relapses in 1 year and 6 months before enrollment, steroid dosage)	$\checkmark$									
Vital signs	$\checkmark$			$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	
Height and weight	$\checkmark$			$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	
Physical examination	$\checkmark$	O	$\checkmark$							
Blood routine examination	$\checkmark$	0		$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	
Urine routine examination	$\checkmark$	0	$\checkmark$							



Fasting blood glucose	$\checkmark$		$\checkmark$							
Serum liver function	$\checkmark$	O	$\checkmark$							
Blood lipid	$\checkmark$	Ø	$\checkmark$							
Serum renal function	$\checkmark$	Ø	$\checkmark$							
Blood EBV-DNA, and CMV antibody	$\checkmark$									$\checkmark$
24hr urinary protein (>3 years old)	$\checkmark$	Ø	V	$\checkmark$	V	$\checkmark$	V	$\checkmark$	$\checkmark$	$\checkmark$
Urinary protein / creatinine	$\checkmark$	Ø	$\checkmark$							
eGFR	$\checkmark$	Ø	$\checkmark$							
Tacrolimus concentration in plasma				V	V	V	V	V		$\checkmark$
Mycophenolic acid concentration in plasma							$\checkmark$			



Chest X-ray	$\checkmark$									
ECG	$\checkmark$									
Markers of hepatitis B and hepatitis C virus	$\checkmark$									
Examination of Mycobacterium tuberculosis and fungi	$\checkmark$									
Biological samples of blood and urine	$\checkmark$						V			$\checkmark$
Drug distribution and measurement			$\checkmark$		$\checkmark$	$\checkmark$			$\checkmark$	$\checkmark$
Guidance on the administration of test drug		$\checkmark$								
Clinical efficacy (relapse or no)			$\checkmark$							



Concomitant medication	$\checkmark$		
Adverse event			$\checkmark$
Record case report form	$\checkmark$		

Remarks:

- 1. Liver function: ALT, TBiL, ALB; Renal function: creatinine, blood Blood urea nitrogen, uric acid, Cystatin C;
- Blood lipids: Triglycerides, cholesterol; Urinary protein / creatinine: morning urine; Markers of hepatitis B and hepatitis C virus: HBsAg, HBeAg, HBcAb, HCV;
- 3. Mycobacterium tuberculosis examination: T-sport; Fungal examination: fungal G test or other; Estimated glomerular filtration rate: eGFR = K × height (cm) / serum creatinine (mg/dL) (see Appendix);
- 4. Visit time window:  $\pm 3$  days for visit 2, and  $\pm 7$  days for other visits;
- \$ Items are applicable to the pediatric patients with combined use of other immunosuppressants before enrollment; 
   Items are optional, depending on the judgment and decision of the investigators;
- 6. This research accepts the examination data from our hospital within 2 weeks before the screening period, and no repeated test is needed.



#### 4.5. Selection of cases

#### 4.5.1. Inclusion criteria

Only those who meet all the conditions listed in this column can be considered for inclusion in this research:

(1) Steroid-sensitive nephrotic syndrome with frequent relapse (FRNS) or steroid dependence (SDNS).

(2) Age: 2-18 years old.

(3) Normal renal function:  $eGFR \ge 90 \text{ mL/min}/1.73\text{m}^2$ .

(4) At the time of enrollment, urinary protein <1+ or urinary protein/creatinine <0.2g/g (<20 mg/mmol) in the morning for 3 consecutive days or more.

(5) No use of tacrolimus, mycophenolate mofetil, cyclosporine A, rituximab or cyclophosphamide within 2 years before enrollment.

#### 4.5.2. Exclusion criteria

Anyone with one of the following conditions cannot be included in this research:

(1) Steroid-resistant nephrotic syndrome (SRNS).

- (2) Family history of nephrotic syndrome, chronic glomerulonephritis or uremia.
- (3) Leukopenia (leukocyte  $\leq 3.0*10^9$ /L).
- (4) Moderate and severe anemia (hemoglobin  $\leq 9.0$  g/dL).
- (5) Thrombocytopenia (platelet count  $<100*10^{12}/L$ ).

(6) Those with positive HBV serological indexes (HBsAg or/and HBeAg or/and HBcAb), positive HCV or abnormal liver function (ALT or total bilirubin exceeding 2 times or more of the upper limit, with a continuous increase for 2 weeks).

(7) There are chronic active infections such as Epstein-Barrvirus, cytomegalovirus or Mycobacterium tuberculosis, and the usage of steroids and immunosuppressive agents may aggravate the state of an illness.



(8) Secondary nephrotic syndrome (such as purpura nephritis, lupus nephritis, etc).

(9) Those who with hematological or endocrine system diseases as well as serious organs illness such as heart, liver or kidney.

(10) Other autoimmune diseases or primary immunodeficiency or tumors.

(11) Those who was known be sensitized to tacrolimus, mycophenolate mofetil, glucocorticoids or any ingredient of the above drugs.

(12) Those who have participated in other clinical trials within three months before enrollment.

(13) Those who was not suitable for participating this study judged by investigator.

#### 4.5.3. Elimination criteria

• Those who fail to take the test drugs as required, with a compliance <80% or >120%.

• Those who cannot cooperate well or complete the follow-up as planned, and those who change the drug dose at will.

#### 4.5.4. Withdrawal criteria

Patients are free to withdraw from the trial at any time without any reason.

Patients must withdraw from this research in the following conditions:

(1) Withdrawal of the Informed Consent Form.

(2) Violation of the inclusion criteria or compliance with the exclusion criteria.

(3) No administration of the test drug according to the Protocol for 14 consecutive days due to various reasons.

(4) For two consecutive times, the measured value of SCr with an interval of at least 4 weeks has increased more than twice the baseline, and  $eGFR < 60mL/min.1.73m^2$ .

(5) The target concentration of tacrolimus or mycophenolate mofetil can not be reached after dose adjustment for one month.

(6) ALT or total bilirubin levels reach more than 2 times of the upper limit after medication, with a continuous increase for 2 weeks; if ALT or total bilirubin levels still rise to more than 2 times of the



upper limit after 2 weeks of liver protection drug treatment, stop the test drug. In case of no recovery after 2 weeks of drug withdrawal, the patient shall withdraw from the test.

(7) Occurrence of unknown adverse events of unacceptable nature, severity and/or duration, or occurrence of known unacceptable adverse events or the occurrence frequency exceeding expectations.

(8) The clinical events or safety-affecting events result in withdrawal from the clinical trial, and the investigators believe that such subjects shall withdraw from the trial.

(9) If pregnancy occurs during treatment, withdraw from the trial.

(10) Unauthorized use of drugs prohibited by this research.

#### 4.5.5. Drop-out and treament

#### 4.5.5.1 Definition of drop-out

All patients who have completed the Informed Consent Form and screened to be enrolled in the trial have the right to withdraw at any time. Whenever and for whatever reason, subjects who fail to complete the observation period specified in the Protocol are considered as drop-out cases, including the following situations:

• The subject has serious adverse events and the clinician believes that he/she should withdraw from the clinical trial;

• The subject shows aggravated condition or has other symptoms affecting the trial observation during the trial, and the clinician believes that he/she should withdraw from the clinical trial;

• Important deviations occur in the implementation of clinical trial protocol, such as poor compliance, which would cause difficulty in evaluating the drug effect;

• The subject is unwilling to continue the clinical trial and asks to withdraw from the clinical trial, or loss of follow-up has occurred although no request to withdraw from the trial is proposed.

#### 4.5.5.2 Treatment of drop-out cases

The investigators shall contact the drop-off subjects by means of visiting, making an appointment for follow-up, calling, letter and so on, to ask the reasons, record the last medication time and complete



the evaluation Items that can be completed. For the cases withdrawing from the trial due to allergy or other adverse reactions and ineffective treatment, the investigators shall take corresponding treatment measures according to the actual situation of the subjects. The investigators shall properly keep the relevant test data of the drop-off cases, not only for filing, but also for full analysis and statistics.

#### 4.5.6. Relevant definitions in inclusion and exclusion criteria

**Steroid-sensitive nephrotic syndrome (SSNS):** Complete remission after 4 weeks of prednisone or prednisolone at standard dose [2mg/kg.d or 60mg/m<sup>2</sup>. d].

**Steroid-resistant nephrotic syndrome (SRNS):** Lack of complete remission at 4 weeks of therapy with daily prednisone or prednisolone at standard dose [2mg/kg.d or 60mg/m<sup>2</sup>. d].

**Steroid-dependent nephrotic syndrome (SDNS):** Two consecutive relapses during therapy with prednisone or prednisolone (either at full dose or during tapering) or within 15 days of prednisone or prednisolone discontinuation

**Frequently relapsing nephrotic syndrome (FRNS):**  $\geq$ 2 relapses per 6 months within 6months of disease onset or 24 relapses per 12 months in any subsequent 12-month period.

**Secondary nephrotic syndrome:** It refers to the nephrotic syndrome with clear causes. Secondary nephrotic syndrome can be caused by autoimmune diseases (such as systemic lupus erythematosus), diabetes, infections (such as bacteria and hepatitis B virus), circulatory system diseases, drug poisoning, etc.

#### 5. Test drugs and their allocation

#### 5.1. Drug name and specifications

Tacrolimus capsules (trade name: Saifukai®, capsules, 1.0 mg/capsule, 0.5 mg/capsule);
 Storage conditions: Keep away from sunlight, and store in a dry place below 25°C after sealing.

(2) Mycophenolate mofetil dispersible tablets (trade name: Saikeping®, tablets, 250 mg/tablet);Storage conditions: Store under 30°C and keep away from sunlight.

(3) Storage conditions of prednisone tablets (tablets, 5 mg/tablet): Keep away from sunlight, and store at room temperature after sealing.



[Prednisone tablets can be replaced by other glucocorticoids during the test, but the dose shall have the same therapeutic effect, for example prednisone 5 mg = prednisolone 5 mg, prednisone 5 mg = methylprednisolone 4 mg, etc.]

#### 5.2. Administration method, dose, route and course of treatment

#### 5.2.1. Initial administration protocol

#### FK506 dose: 0.05-0.10mg/kg/day, BID

Maintained concentration: In the induction period (the first six months after treatment) (visit 2, 3, 4, 5 and 6), the trough plasma concentration of tacrolimus is 5 - 10 ng/mL;

In the maintenance period, drug dose is gradually reduced when the patient's condition is stable:

In the last six months after administration (visit 7, 8, and 9), the trough concentration is <5 ng/mL

MMF dose: 20-30 mg/kg/day, BID

Plasma concentration (AUC) [Formula: MPA-AUC =7.75+(6.49\*C0)+(0.76\*C0.5)+(2.43\*C2)]

Maintained concentration: In the induction period (the first six months after treatment) (visit 2, 3, 4,

5 and 6)

#### MPA-AUC=30 - 50 µg.h/mL

# In the maintenance period, drug dose is gradually reduced when the patient's condition is stable:

#### In the last six months after administration (visit 7, 8, and 9), MPA-AUC≤40 µg.h/mL

**Prednisone dose:** The initial dose is 1.0-1.5 mg/kg every other day or 0.5-0.75 mg/kg every day. The dose shall be reduced after 4 weeks by 0.25 mg/kg (qd alt) or 0.125 mg/kg (every day) every 2-4 weeks. If the condition is stable, continue to reduce to 5mg (body surface area  $> 1 \text{ m}^2$ ) and 2.5mg (body surface area  $< 1 \text{ m}^2$ ) qd alt. Maintain at such doses until this research is completed.

#### 5.2.2. Treatment of relapses

If the disease is complicated with infection in the relapse for the pediatric patients, anti-infection treatment can be given first. After infection control, if the disease still shows relapse, the prednisone



dose shall be restored to 1.0-1.5 mg/kg per day, with a maximum dose  $\leq$ 60mg; If there is no infection at the time of relapse in the pediatric patients, the prednisone dose should be restored to 1.0-1.5 mg/kg per day directly, with a maximum dose  $\leq$ 60mg. 5-7 days after the urine protein turns into negative results, the prednisone dose is reduced by 1.0-1.5 mg/kg every other day or 0.5-0.75mg/kg per day  $\times$  4 weeks. Then the dose is reduced as per the above steroid reduction method, while the dose of MMF or FK506 remains unchanged.

#### 5.2.3. Dose adjustment of tacrolimus (FK506)

5.2.3.1 Adjust the dose according to the trough plasma concentration of tacrolimus. If the trough plasma concentration cannot meet the target concentration, it can be increased by adding Wuzhi capsules, ketoconazole, Hexin Shuang or cimetidine. If the trough plasma concentration of tacrolimus is >10 ng/mL, the dose of tacrolimus shall be reduced, and the trough concentration shall be rechecked after one week to adjust the target concentration. After treatment, the increase of SCr  $\geq$  30% of the basic value and eGFR < 60mL/min.1.73m<sup>2</sup> (excluding non-drug factors) shall prompt tacrolimus dose reduction by 50%. If the concentration still fails to reach the target after tacrolimus dose adjustment for one month, the subject shall withdraw from the trial.

5.2.3.2 If the trough plasma concentration of tacrolimus in visit 7 is  $\geq$  5 ng/mL, the dose of tacrolimus needs to be reduced by 20%-30%, and the trough concentration shall be rechecked in visit 8. If the trough concentration of tacrolimus is still  $\geq$  5 ng/mL in visit 8, it is necessary to continue to reduce the dose of tacrolimus by 20%-30%, and recheck this concentration in visit 9.

#### 5.2.4. Dose adjustment of mycophenolate mofetil (MMF)

5.2.4.1 Adjust the dose according to the plasma concentration of mycophenolic acid. If MPA-AUC fails to meet the target, increase the oral dose of mycophenolate mofetil, but the maximum dose shall not exceed 1.0g each time, BID. Recheck MPA-AUC after 1 week and adjust the drug administration to meet the target concentration. If the patient has blood neutrophils less than 1300 per  $\mu$ L or total leukocytes less than 3000 per  $\mu$ L, diarrhea or severe infection, the dose of mycophenolate mofetil needs to be reduced by 25%. If the side effect persists, it shall be adjusted to half of the original dose. If the case of mycophenolate mofetil dose adjustment, the plasma concentration shall be measured according to the judgment of the investigators. If the concentration still fails to reach the target after



mycophenolate mofetil dose adjustment for one month, the subject shall withdraw from the trial. 5.2.4.2 If MPA-AUC is  $\geq$  40 ng/mL in visit 6, the dose of mycophenolate mofetil needs to be reduced by 20%-30%. After that, retest is no longer required.

#### 5.3. concomitant medication

• Statins are allowed for use during this research, which can be increased or decreased according to the blood lipid status.

- Various anticoagulant drugs are allowed for use during this research.
- Immunosuppressants other than the test drug are prohibited for use.
- Plasma exchange and biological agents are prohibited for treatment.
- IVIG can be used during this research, but the reason needs to be recorded.

• When hypertension occurs during treatment, angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) cannot be used, but dihydropyridine calcium antagonists,  $\beta$ -receptor blocker, diuretic and/or  $\alpha$ -receptor blocker can be used for control, with a target blood pressure of: <120/80 mmHg.

• Liver protection drugs are allowed for use during this research.

• If blood glucose rises during treatment, the blood glucose shall be actively controlled with hypoglycemic drugs.

• Various Chinese herbal medicines are prohibited for the treatment of kidney diseases during this research.

• The investigators shall ask the subjects to bring all the drugs they are taking at the time of follow-up, so as to check the concomitant medication for the subjects. For the other drugs or treatments that must be continued for the complicated diseases, the drug name (or other treatment name), dosage, times of use and time must be recorded on the Clinical Study Report for analysis and reporting during summary.



#### 5.4. Medication adherence

The medication adherence is calculated as follows, and shall be ranging from 80% to 120%:

adherence =  $\frac{\text{actual administration}}{\text{planned administration}} \times 100\%$ 

#### 6. Evaluation of efficacy and safety

#### 6.1. Primary efficacy outcomes

1-year relapse-free survival

#### 6.2. Efficacy evaluation

#### 6.2.1. Primary observation outcomes: 1-year relapse-free survival

#### 6.2.2. Secondary observation outcomes:

(1) Frequency of relapses; the time of the first relapse after enrollment; relapse-free survival in the first six months after enrollment;

(2) Renal function: Serum creatinine and glomerular filtration rate (eGFR, see Appendix 1 for the calculation method)

(3) Cumulative steroid dosage: The total amount of steroids taken during this research and the total amount of steroids in the first half of the year

(4) Others: Blood pressure (see Appendix 2 for details), height, weight, blood lipid, hemoglobin, blood albumin, urinary protein/creatinine (morning urine), etc.

(5) Adverse reaction

(6) 24hr urinary protein quantification (applicable to subjects > 3 years old)

#### 6.2.3. Efficacy criteria

Complete remission (CR): Completely normal in blood biochemistry test and urine examination;

Partial remission (PR): Urinary protein positive < (+++);

No remission (NR): Urinary protein positive  $\geq$  (+++).



#### 6.2.4. Relapse criteria

For 3 consecutive days, morning urinary protein changes from negative to (+++) or (++++), or 24hr urinary protein quantification  $\geq$  50 mg/kg, or urinary protein/creatinine (mg/mg)  $\geq$ 2.0.

#### 6.3. Safety evaluation

Changes of vital signs: Respiration and heart rate.

Various indexes in laboratory examination: Blood and urine routine examination, liver function, renal function, ECG, chest X-ray examination.

Clinically reported adverse events and adverse reactions.

#### 7. Statistical analysis

#### 7.1. Analysis data set

Full analysis set (FAS): It refers to the set of eligible cases and drop-off cases. The cases are required to have evaluation data after at least one treatment, but excluding the eliminated cases. Per-protocol set (PPS): It refers to the set of cases that meet the inclusion criteria, do not meet the exclusion criteria and complete the treatment plan, that is, the analysis of cases that meet the trial protocol, have good compliance and complete the specified content in CRF (PP analysis).

Safety set (SS): It refers to the actual data with safety index records after receipt of at least one treatment. The missed safety values shall not be carried forward. It includes some eliminated cases that can be evaluated, such as those whose age exceeds the inclusion criteria, but excludes those whose safety judgment cannot be made due to the use of banned drugs. For the incidence of adverse reactions, the number of cases in the safety set is used as the denominator.

#### 7.2. General considerations of date analyses

#### 7.2.1. General Statistical methods

SAS 9.4 software is adopted for Statistical analysis. Two-sided test is adopted for all Statistical tests. If the P value is less than 0.05, the tested difference will be considered "Statistically significant" (unless otherwise specified).



**Descriptive analysis:** Sort out and summarize a large number of data obtained from the survey to find out the internal law of these data - centralized trend and decentralized trend. Single factor analysis is mainly carried out with the help of statistics represented by various data, such as mean and percentage.

#### 7.2.2. Statistical inference method

• The description of quantitative indicators includes the calculation of the mean, standard deviation, median, minimum value, maximum value, lower quartile (Q1), upper quartile (Q3), as well as the number and percentage of various types of classification indicators.

• In the comparison of the general conditions between the two groups, appropriate methods shall be adopted for analysis according to the type of indicators. The group t-test or Wilcoxon rank sum test is used for the comparison of quantitative data between two groups; Chi-square test or exact probability method is used for classification data; Wilcoxon rank sum test or CMH test is used for hierarchical data.

• The report is mainly expressed in tables: The tables are self-evident, that is, they have table titles, table notes and number of cases.

#### 8. Data handling conventions

Data conversion:

Age (years) = (date of signing of informed consent form - date of birth + 1) / 365.25, rounded down.

Drug-related definitions are: definitely related, probably related, and possibly related.

Missing date: Since it is survival analysis data, it does not need to be filled. Missing text-type data is displayed as "" in the list. Numeric data is missing from the list with "." to display. If the data is recorded as "not applicable"/"NA" and "unable to assess"/"NK", the data will be displayed as raw records when described in the inventory, and processed as missing data for Statistical analysis.

Outlier: In general, all assay results will be used for Statistical analysis. If there is a clear outlier caused by special reasons and affects the Statistical analysis, it is missing and marked in the



Statistical analysis results / report.

#### 8.1. Content of Statistical analysis

#### 8.1.1. Basic value equilibrium analysis

The demographic characteristics, general conditions and baseline conditions (basic value indicators) of the two groups are analyzed to measure the comparability of the two groups. Group t-test or Wilcoxon rank sum test is used for measurement data; Wilcoxon rank sum test is used for classification or grade data;  $\chi^2$  test or Fisher test is used for classification data.

#### 8.1.2. Effectiveness analysis

All effectiveness analysis/global indicators will be based on ITT principles, and FAS is adopted, for only the adjudicated endpoint events. The investigators are required to report all the potential endpoint events in eCRF.

#### 8.1.3. Primary efficacy analysis

Logrank test is used for the analysis of relapse-free survival rate which is then used as a covariate for stratification by Sites. HR and its 95% confidence interval (CI) are calculated with Cox proportional hazard model to estimate the efficacy, the confidence interval is applied to verify the superiority of the experimental group and the control group, with a cut-off value of 1 (risk ratio). The model incorporates the same covariate as the Logrank test for fitting, and the definition method of covariates is also the same as that in the Logrank test. The Kaplan-Meier curve of relapse-free survival is drawn by treatment groups. The 1-year relapse-free survival rate and its confidence interval are then calculated.

#### Calculation rules for the main efficacy indicators:

• If relapse occurred within 9 visits (within  $364 \pm 7$  days) or unscheduled visits within 365 days of randomization, defined as the occurrence of endpoint events. Time of relapse = date of relapse - Random date + 1, calculated by days.

• If the visit stipulated in the protocol was not completed within 9 visits (within  $364 \pm 7$  days) due to loss of follow-up midway or withdrawal or other reasons, it is defined as censoring. Time of



censoring = date of withdrawal - random date + 1, calculated by days.

• If the visit stipulated in the protocol was not completed within 9 visits (within  $364 \pm 7$  days) due to death in the trial, it is defined as censoring. Time of censoring = Death date - random date + 1, calculated by days.

• If the visit stipulated in the protocol was completed and there is no relapse within 9 visits (within  $364 \pm 7$  days), it is defined as censoring. Time of censoring = date of visit 9 (within  $364 \pm 7$  days) - random date + 1, calculated by days.

#### 8.1.4. Secondary efficacy analysis

Secondary outcomes (renal function; cumulative steroid dosage; blood pressure; height; body weight; blood lipids; hemoglobin; serum albumin; urinary protein/creatinine (morning urine); 24hr urinary protein quantification (applicable to subjects > 3 years old); frequency of relapses; the time of the first relapse after enrollment; relapse-free rate in the first six months after enrollment) are described and compared with use of the above general Statistical methods, and the adverse reactions are analyzed by descriptive analysis.

#### 8.1.5. Other analysis

(1) Case distribution: Different data sets in each group, case distribution in each Site, comparison of total drop-off rate, detailed list of termination reasons, and descriptive analysis.

(2) Compliance analysis: Compare whether the two groups of patients take the test drugs on time and in quantity, whether they take the drugs and foods prohibited in the Protocol, and conduct the same descriptive analysis as well as  $\chi^2$  test or Fisher test for analysis.

(3) The incidence of drug withdrawal or drug change due to adverse reactions in the clinical trial shall be analyzed with  $\chi^2$  test or Fisher test. The efficacy in the long-term follow-up after the trial is evaluated by descriptive analysis and  $\chi^2$  test or Fisher test.

#### 8.1.6. Safety analysis

Safety analysis mainly adopts safety set. All adverse events are coded by MedDRA 20.0 to describe the total number and incidence of adverse events (including serious adverse events), and the



frequency table is used to describe the frequency, severity of each adverse event and its relationship with the treatment. Adverse events relevant (related, probably related, and possibly relayed) to this research treatment are described and listed separately. Other safety indicators will also be described and summarized. The laboratory changes with clinical significance will be counted as AE.



#### 9. Statistical analysis results

#### 9.1. Research overview

Table 1. Distribution of subjects at each site (All enrolled subjects)

Research Site	Group	No. of subjects enrolled	No. of subjects drop-out	Drop-out rate	No. of subjects eliminated	Elimination rate	No. of subjects completed
Site 1	Experimental group						
	Control group						
	Total						
Site 2	Experimental group						
	Control group						
	Total						
Total	Experimental group						
	Control group						
	Total						

Note: 1. The Site name is not displayed in following table, only the site number. Same below. 2. No. of subjects completed = No. of subjects enrolled - No. of subjects drop-out. Elimination refers to subjects who complete the trial, but were not included in the PPS. Subjects who withdrew due to the endpoint event were considered to have completed the trial. 3. Drop-out rate = No. of subjects drop-out / No. of subjects enrolled; Elimination rate = No. of subjects enrolled.



#### Table 2. Distribution of subjects at each site

	PPS				FAS	SS			
Site	Experimental group	Control group	Total	Experimental group	Control group	Total	Experimental group	Control group	Total
Site 1									
Site 2									
Total									

#### Table 3. Trial completion and distribution of analysis data set (All enrolled subjects)

Items	Indicator	Experimental group	Control group	Total
No. of subjects enrolled	Yes			
	No			
Complete 1 week follow-up	Yes			
	No			
Complete 4 week follow-up	Yes			
	No			
Complete 8 week follow-up	Yes			
	No			
Complete 16 week follow-up	Yes			
	No			
Complete 24 week follow-up	Yes			
	No			
Complete 32 week follow-up	Yes			
	No			
Complete 40 week follow-up	Yes			
	No			
Complete 52 week follow-up	Yes			
	No			
Trial completion	Yes			

Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.



Items	Indicator	Experimental group	Control group	Total
	No			
Treatment discontinuation reason	Subject voluntarily withdrew prematurely			
	Decision by the investigator			
	Poor compliance that decided by the investigator			
	Meet the exclusion criteria, or did not meet the inclusion criteria			
	Refusal to continue trial participation			
	Lack of efficacy			
	Adverse events			
	Lost to follow-up			
	Death			
	Other			
FAS				
PPS				
SS				

Note: Follow-up time (years) = (last visit date - random date + 1) / 365.25. Complete 1 week follow-up: follow-up duration  $\ge$  1 week, and so on.

### 9.2. Demographic characteristics (FAS)

Table 4. Baseline demographics

Items	Indicator	Experimental group	Control group	Total
Age (years)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
Gender	male n (%)			



Items	Indicator	Experimental group	Control group	Total
	Female n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Ethnicity	Han n (%)			
	Others n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Source of disease	Outpatient n (%)			
	Ward n (%)			
	Total (Missing)			
	Statistics			
	P-value			

## Table 5. Baseline vital signs

Items	Indicator	Experimental group	Control group	Total
Height (cm)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
Weight (kg)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			



Items	Indicator	Experimental group	Control group	Total
	Min, Max			
	Statistics			
	P-value			
BMI (kg/m <sup>2</sup> )	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
Femperature (°C)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
Systolic blood pressure (mmHg)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
Diastolic blood pressure (mmHg)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			



Items	Indicator	Experimental group	Control group	Total
	Min, Max			
	Statistics			
	P-value			
Heart rate (times/min)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
Respiratory rate (times/minute)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			

## Table 6. Family history and personal history

Items	Indicator	Experimental group	Control group	Total
Family history	No n (%)			
	Yes n (%)			
	Total (Missing)			
	Statistics			
	P-value			
History of drug allergy	No n (%)			
	Yes n (%)			
	Total (Missing)			



Items	Indicator	Experimental group	Control group	Total
	Statistics			
	P-value			
History of surgery	No n (%)			
	Yes n (%)			
	Total (Missing)			
	Statistics			
	P-value			
History of pet ownership	No n (%)			
	Yes n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Number of gestation	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
Number of parturition	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
Birth weight (kg)	N (Missing)			
	Mean (SD)			



tems	Indicator	Experimental group	Control group	Total
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
History of dystocia	No n (%)			
	Yes n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Feeding	Mixed feeding n (%)			
	Single feeding n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Partial eclipse	No n (%)			
	Yes n (%)			
	Total (Missing)			
	Statistics			
	P-value			
History of growth and development	Normal n (%)			
	Abnormal n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Vaccination history	No n (%)			
	Yes n (%)			
	Total (Missing)			



Items	Indicator	Experimental group	Control group	Total
	Statistics			
	P-value			

Items	Indicator	Experimental group	Control group	Total
History of other diseases and concomitant medications	No n (%)			
	Yes n (%)			
	Total (Missing)			
	Statistics			
	P-value			
History of nephrotic syndrome (years)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
History of nephrotic syndrome (Number of relapses in the past 1 year)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
History of nephrotic syndrome (Number of relapses in the past 6 months)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			



Items	Indicator	Experimental group	Control group	Total
	Min, Max			
	Statistics			
	P-value			

Note: History of other diseases and concomitant medications: history of diseases other than the nephrotic syndrome, such as pneumonia, cardiovascular, diabetes, purpura and enuresis, etc.

Table 8. Visual palpation of physical examination Items

Items	Indicator	Experimental group	Control group	Total
Heart	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Superficial lymph node	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Skin and sclera	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			



Thyroid gland	Normal n (%)
	Abnormal but not clinically significant n (%)
	Abnormal and clinically significant n (%)
	Not tested n (%)
	Total (Missing)
	Statistics
	P-value
Limbs and spine	Normal n (%)
	Abnormal but not clinically significant n (%)
	Abnormal and clinically significant n (%)
	Not tested n (%)
	Total (Missing)
	Statistics
	P-value
Lung, abdomen and back	Normal n (%)
	Abnormal but not clinically significant n (%)
	Abnormal and clinically significant n (%)
	Not tested n (%)
	Total (Missing)
	Statistics
	P-value
Nervous system	Normal n (%)
	Abnormal but not clinically significant n (%)
	Abnormal and clinically significant n (%)
	Not tested n (%)
	Total (Missing)
	Statistics
	P-value
Other	Normal n (%)

Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.



Abnormal but not clinically significant n (%)	
Abnormal and clinically significant n (%)	
Not tested n (%)	
Total (Missing)	
Statistics	
P-value	

Table 9. Diagnostic consultation of physical examination Items

Items	Indicator	Experimental group	Control group	Total
Defecation	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Fever/dizziness/vertigo	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Dry mouth and eyes	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			



	P-value
Gastrointestinal digestion	Normal n (%)
	Abnormal but not clinically significant n (%)
	Abnormal and clinically significant n (%)
	Not tested n (%)
	Total (Missing)
	Statistics
	P-value
Myalgia/muscle weakness	Normal n (%)
	Abnormal but not clinically significant n (%)
	Abnormal and clinically significant n (%)
	Not tested n (%)
	Total (Missing)
	Statistics
	P-value
Arthralgia/arthritis	Normal n (%)
	Abnormal but not clinically significant n (%)
	Abnormal and clinically significant n (%)
	Not tested n (%)
	Total (Missing)
	Statistics
	P-value
Dry/itchy skin	Normal n (%)
	Abnormal but not clinically significant n (%)
	Abnormal and clinically significant n (%)
	Not tested n (%)
	Total (Missing)
	Statistics
	P-value



Other	Normal n (%)
	Abnormal but not clinically significant n (%)
	Abnormal and clinically significant n (%)
	Not tested n (%)
	Total (Missing)
	Statistics
	P-value

# 9.3. Baseline examinations (FAS)

### Table 10. DNA/antibody tests

Items	Indicator	Experimental group	Control group	Total
Blood EBV-DNA	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Blood CMV antibody	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			
IgM	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			



Not tested n (%)
Total (Missing)
Statistics
P-value
Normal n (%)
Abnormal but not clinically significant n (%)
Abnormal and clinically significant n (%)
Not tested n (%)
Total (Missing)
Statistics
P-value

Table 11. Hepatitis virus

IgG

Items	Indicator	Experimental group	Control group	Total
HBs-Ag	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Anti-HCV	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			



# Table 12. Examination of mycobacterium tuberculosis and fungi

Items	Indicator	Experimental group	Control group	Total
Mycobacterium tuberculosis test	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Fungal examination	Fungal G test n (%)			
	Fungal other n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Fungal examination result	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			

Table 13. Urine test

Items	Indicator	Experimental group	Control group	Total
24hr urine protein (>3 years old)	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			



	Statistics
	P-value
Urine protein/serum creatinine	Normal n (%)
	Abnormal but not clinically significant n (%)
	Abnormal and clinically significant n (%)
	Not tested n (%)
	Total (Missing)
	Statistics
	P-value

## Table 14. Glomerular filtration rate

Items	Indicator	Experimental group	Control group	Total
Examine or not	No n (%)			
	Yes n (%)			
	Total (Missing)			
	Statistics			
	P-value			
eGFR	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			

## Table 15. Retained biological samples of blood and urine

Items	Indicator	Experimental group	Control group	Total
Retained biological samples of blood and urine	No n (%)			
	Yes n (%)			
Hansahan 7hanan ikus dana Dhamasanti ad Ca. I tal				



## Total (Missing)

Statistics

P-value

## Table 16. Chest X-ray

Items	Indicator	Experimental group	Control group	Total
Result	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			

### Table 17. ECG examinations

Items	Indicator	Experimental group	Control group	Total
Result	Normal n (%)			
	Abnormal but not clinically significant n (%)			
	Abnormal and clinically significant n (%)			
	Not tested n (%)			
	Total (Missing)			
	Statistics			
	P-value			

## Table 18. Primary diagnosis

Items	Indicator	Experimental group	Control group	Total
Primary diagnosis	Steroid-sensitive nephrotic syndrome (SSNS) n (%)			
	Steroid-resistant nephrotic syndrome (SRNS) n (%)			
	Secondary nephrotic syndrome n (%)			



Steroid-dependent nephrotic syndrome (SDNS) n (%) Frequently relapsing nephrotic syndrome (FRNS) n (%) Other nephrotic syndrome n (%) Total (Missing) Statistics P-value

# 9.4. Efficacy analysis (FAS/PPS)

## 9.4.1. Primary efficacy indicators: 1-year relapse-free survival rate

Table 19. 1-year relapse-free survival analysis

		FAS	5	PPS	5
Items	Indicator	Experimental group	Control group	Experimental group	Control group
1-year recurrence time (days)	N (Missing)				
	Endpoint event (%)				
	Censoring (%)				
	Median survival time				
	95%CI				
	Q1, Q3				
	Log-rank test				
	P-value				
Cox regression analysis	Hazard Ratio				
	95%CI				
	Wald chi-square				
	P-value				

Note: The independent variables of Cox regression analysis are group and Site. Same below.



Figure 1. 1-year relapse-free survival analysis chart (FAS)

Figure 2. 1-year relapse-free survival analysis chart (PPS)



# 9.4.2. Secondary efficacy indicators

# 9.4.2.1. The first relapse survival analysis after enrollment

Table 20. The time of the first relapse after enrollment

		FAS		PPS	
Items	Indicator	Experimental group	Control group	Experimental group	Control group
The time of the first relapse after enrollment (days)	N (Missing)				
	Mean (SD)				
	Median				
	Q1, Q3				
	Min, Max				
	95%CI				
	P-value				

Note: The time of first relapse after enrollment (days) = Date of first relapse after enrollment - Random date + 1.

## Table 21. The first relapse survival analysis after enrollment

		FAS		PPS	5
Items	Indicator	Experimental group	Control group	Experimental group	Control group
The time of the first relapse after enrollment (days)	N (Missing)				
	Endpoint event (%)(%)				
	Censoring (%)				
	Median survival time				
	95%CI				
	Q1, Q3				
	Log-rank test				
Cox regression analysis	Hazard Ratio				
	95%CI				
	Wald Chi-square				
	P-value				



# 9.4.2.2. 6-month relapse-free survival analysis after enrollment

Table 22. 6-month relapse-free survival analysis after enrollment

		FAS		PPS	
Items	Indicator	Experimental group	Control group	Experimental group	Control group
6-month recurrence time (days)	N (Missing)				
	Endpoint event (%)(%)				
	Censoring (%)				
	Median survival time				
	95%CI				
	Q1, Q3				
	Log-rank test				
Cox regression analysis	Hazard Ratio				
	95%CI				
	Wald Chi-square				
	P-value				

Figure 3. 6-month relapse-free survival analysis chart (FAS)

Figure 4. 6-month relapse-free survival analysis chart (PPS)



# 9.4.2.3. Serum renal function

Table 23. Changes in eGFR relative to baseline at each visit

			FAS		PPS			
Items	Indicator	Experimental group	Control group	Total	Experimental group	Control group	Total	
Baseline	N (Missing)							
	Mean (SD)							
	Median							
	Q1, Q3							
	Min, Max							
	95%CI							
Between-group comparison in baseline	Statistics							
	P-value							
Visit 2/Day 7±3	N (Missing)							
	Mean (SD)							
	Median							
	Q1, Q3							
	Min, Max							
	95%CI							
Between-group comparison in Visit 2/Day $7\pm3$	Statistics							
	P-value							
Change in Visit 2/Day $7\pm 3$ from baseline	N (Missing)							
	Mean (SD)							
	Median							
	Q1, Q3							
	Min, Max							
	95%CI							
Pre- and post-treatment comparison of intra-group	Statistical method							
	Statistics							
	P-value							
Comparison of changes between groups pre- and post-treatment	Statistics							
	P-value							
Visit 4/Day 56±7	N (Missing)							
	Mean (SD)							
Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.		56 / 83						



			FAS			PPS	
tems	Indicator	Experimental group	Control group	Total	Experimental group	Control group	Total
	Median						
	Q1, Q3						
	Min, Max						
	95%CI						
Between-group comparison in Visit 4/Day 56 $\pm7$	Statistics						
	P-value						
Change in Visit 4/Day 56 $\pm$ 7 from baseline	N (Missing)						
	Mean (SD)						
	Median						
	Q1, Q3						
	Min, Max						
	95%CI						
Pre- and post-treatment comparison of intra-group	Statistical method						
	Statistics						
	P-value						
Comparison of changes between groups pre- and post-treatment	Statistics						
	P-value						
/isit 5/Day 112±7	N (Missing)						
	Mean (SD)						
	Median						
	Q1, Q3						
	Min, Max						
	95%CI						
Between-group comparison in Visit 5/Day 112 $\pm$ 7	Statistics						
	P-value						
Change in Visit 5/Day 112 $\pm$ 7 from baseline	N (Missing)						
	Mean (SD)						
	Median						
	Q1, Q3						
	Min, Max						
	95%CI						

Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.



			FAS		PPS			
Items	Indicator	Experimental group	Control group	Total	Experimental group	Control group	Tota	
Pre- and post-treatment comparison of intra-group	Statistical method							
	Statistics							
	P-value							
Comparison of changes between groups pre- and post-treatment	Statistics							
	P-value							
Visit 6/Day 168±7	N (Missing)							
	Mean (SD)							
	Median							
	Q1, Q3							
	Min, Max							
	95%CI							
Between-group comparison in Visit 6/Day 168 $\pm$ 7	Statistics							
	P-value							
Change in Visit 6/Day 168 $\pm$ 7 from baseline	N (Missing)							
	Mean (SD)							
	Median							
	Q1, Q3							
	Min, Max							
	95%CI							
Pre- and post-treatment comparison of intra-group	Statistical method							
	Statistics							
	P-value							
Comparison of changes between groups pre- and post-treatment	Statistics							
	P-value							
Visit 7/Day 224±7	N (Missing)							
	Mean (SD)							
	Median							
	Q1, Q3							
	Min, Max							
	95%CI							
Between-group comparison in Visit 7/Day 224 $\pm$ 7	Statistics							
Han and an 7th an an a thread and Discourse and the Local Constant								



			FAS			PPS	
Items	Indicator	Experimental group	Control group	Total	Experimental group	Control group	Total
	P-value						
Change in Visit 7/Day 224 $\pm$ 7 from baseline	N (Missing)						
	Mean (SD)						
	Median						
	Q1, Q3						
	Min, Max						
	95%CI						
Pre- and post-treatment comparison of intra-group	Statistical method						
	Statistics						
	P-value						
Comparison of changes between groups pre- and post-treatment	Statistics						
	P-value						
Visit 8/Day 280±7	N (Missing)						
	Mean (SD)						
	Median						
	Q1, Q3						
	Min, Max						
	95%CI						
Between-group comparison in Visit 8/Day $280\pm7$	Statistics						
	P-value						
Change in Visit 8/Day $280 \pm 7$ from baseline	N (Missing)						
	Mean (SD)						
	Median						
	Q1, Q3						
	Min, Max						
	95%CI						
Pre- and post-treatment comparison of intra-group	Statistical method						
	Statistics						
	P-value						
Comparison of changes between groups pre- and post-treatment	Statistics						
	P-value						

Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.



			FAS			PPS	
Items	Indicator	Experimental group	Control group	Total	Experimental group	Control group	Total
Visit 9/Day $364 \pm 7$	N (Missing)						
	Mean (SD)						
	Median						
	Q1, Q3						
	Min, Max						
	95%CI						
Between-group comparison in Visit 9/Day $364 \pm 7$	Statistics						
	P-value						
Change in Visit 9/Day $364 \pm 7$ from baseline	N (Missing)						
	Mean (SD)						
	Median						
	Q1, Q3						
	Min, Max						
	95%CI						
Pre- and post-treatment comparison of intra-group	Statistical method						
	Statistics						
	P-value						
Comparison of changes between groups pre- and post-treatment	Statistics						
	P-value						

Figure 5. Quantitative variables of eGFR at each visit

Table 24. Change in Scr from baseline at each visit Ibid. Same below.

Figure 6. Quantitative variables of Scr at each visit

Table 25. Change in serum uric acid from baseline at each visit



Figure 7. Quantitative variables of serum uric acid at each visit

Table 26. Change in blood urea nitrogen from baseline at each visit

Figure 8. Quantitative variables of blood urea nitrogen at each visit

Table 27. Change in serum cystatin C from baseline at each visit

Figure 9. Quantitative variables of serum cystatin C at each visit

## 9.4.2.4. Cumulative steroid dosage

Table 28. Total amount of steroids taken during the study

Items	Indicator	Experimental group	Control group	Total
Total amount of steroids taken during the study	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			

Table 29. Tota	amount of steroids	taken during	6 months after	enrollment

Items	Indicator	Experimental group	Control group	Total
Total amount of steroids taken during 6 months after enrollment	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			



Items	Indicator	Experimental group	Control group	Total
	Statistics			
	P-value			

# 9.4.2.5. Vital signs

Table 30. Change in systolic blood pressure from baseline at each visit

Table 31. Change in diastolic blood pressure from baseline at each visit

Table 32. Change in height from baseline at each visit

Table 33. Change in weight from baseline at each visit

## Table 34. Height percentile

Items	Indicator	Experimental group	Control group	Total
Baseline	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
/isit 5/Day 112±7	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value [1997]			
Visit 9/Day 364 $\pm$ 7	N (Missing)			
	Mean (SD)			
	Median			



Items	Indicator	Experimental group	Control group	Total
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			

Note: Data from the external file "XX".

## 9.4.2.6. Blood lipid

Table 35. Change in triglyceride from baseline at each visitTable 36. Change in total cholesterol from baseline at each visit

## 9.4.2.7. Haemoglobin and albumin (ALB)

Table 37. Change in haemoglobin from baseline at each visitTable 38. Change in ALB from baseline at each visit

### 9.4.2.8. Urine test

Table 39. Change in 24hr urine protein (>3 years old) from baseline at each visit Table 40. Change in urine protein/creatinine (morning urine) from baseline at each visit

## 9.4.2.9. Serum liver function and fasting blood glucose

Table 41. Change in glutamyl transpeptidase (GT) from baseline at each visit
Table 42. Change in alanine aminotransferase (ALT) from baseline at each visit
Table 43. Change in aspartate aminotransferase (AST) from baseline at each visit
Table 44. Change in lactate dehydrogenase from baseline at each visit
Table 45. Change in total bilirubin from baseline at each visit
Table 46. Change in direct bilirubin from baseline at each visit
Table 47. Change in alkaline phosphatase from baseline at each visit
Table 48. Change in total protein from baseline at each visit



Table 49. Change in globulin from baseline at each visitTable 50. Change in fasting blood glucosefrom baseline at each visit

### 9.4.2.10. Blood routine examination

Table 51. Change in leukocyte count (WBC) from baseline at each visitTable 52. Change in erythrocyte count (RBC) from baseline at each visitTable 53. Change in platelet count (PLT) from baseline at each visitTable 54. Change in lymphocyte percentage (LY) from baseline at each visit

## 9.4.2.11. Urine routine examination

Table 55. Change in leukocyte from baseline at each visitTable 56. Change in erythrocyte from baseline at each visitTable 57. Change in pH from baseline at each visitTable 58. Change in urine protein from baseline at each visit

## 9.4.2.12. Plasma concentration

Table 59. Change in tacrolimus concentration in plasma from baseline at each visitTable 60. Change in mycophenolic acid concentration in plasma from baseline at each visit

## 9.4.3. Disease remission

Table 61. Disease remission at each visit

Items	Indicator	Experimental group	Control group	Total
Visit 1/Day 0	Complete remission (CR) n (%)			
	Partial remission (PR) n (%)			
	Non remission (NR) n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Visit 2/Day 7 $\pm$ 3	Complete remission (CR) n (%)			



Partial remission (PR) n (%) Non remission (NR) n (%) Total (Missing) Statistics

P-value

9.5. Safety analysis (SS)

...

## 9.5.1. Adverse event (AE)

Table 62. Between-group comparison of AE

Items	Experimental group Control group			P-value			
	No. of AEs	No. of subjects	Percentage	No. of AEs	No. of subjects	Percentage	
AE							
AE of severe severity							
Drug-related AE							
Serious adverse event (SAE)							
Drug-related SAE							
Drop-out due to AE							
Drop-out due to SAE							
Note 1: The definitions related to drugs are "definitely related", "probably related", "possibly related", "unlikely related" and "not related".							

Note 2: The data of SAE that cause the drop-out came from the external file "XX".

## Table 63. characteristics of AE in each group

Items			Experimental group			Control group		P-value
		No. of AEs	No. of subjects	Incidence	No. of AEs	No. of subjects	Incidence	
Relationship with study drug	Definitely related							
	Probably related							
	Tiobably Telated							



Items			Experimental group			Control group		P-value
		No. of AEs	No. of subjects	Incidence	No. of AEs	No. of subjects	Incidence	
	Possibly related							
	Unlikely related							
	Not related							
Outcome	Recovered/resolved							
	Recovered/resolved with sequelae							
	Not recovered							
	Recovering/resolving							
	Death							
	Unknown							

## Table 64. Between-group comparison of SAE

Items	Ex	perimental group	(n=XX)		Control group (n=2	XX)		Total (n=XX)		P-value
	No. of AEs	No. of subjects	Incidence (%)	No. of AEs	No. of subjects	Incidence (%)	No. of AEs	No. of subjects	Incidence (%)	
Results in death										
Requires hospitalization										
Prolongs hospitalization										
Disability										
Dysfunction										
Congenital malformation										
Life threatening										
Other										

# Table 65. Summary of AE base on SOC and PT coding

Indicator	Ex	perimental group (n=XX)		Control group (n=2	XX)	Total (n=XX)		
	No. of AEs	No. of subjects Incidence (%)	No. of AEs	No. of subjects	Incidence (%) No. of AEs	No. of subjects	Incidence (%)	P-value

AE



Indicator	Ex	Experimental group (n=XX)			Control group (n=XX)			Total (n=XX)		
	No. of AEs	No. of subjects	Incidence (%)	No. of AEs	No. of subjects	Incidence (%)	No. of AEs	No. of subjects	Incidence (%)	P-value
SOC1										
PT1										
PT2										
SOC2										
PT1										
PT2										

## Table 66. Summary of adverse reactions base on SOC and PT coding

Indicator	Ex	Experimental group (n=XX)			Control group (n=XX)			Total (n=XX)		
	No. of AEs	No. of subjects	Incidence (%)	No. of AEs	No. of subjects	Incidence (%)	No. of AEs	No. of subjects	Incidence (%)	P-value
Adverse event										
SOC1										
PT1										
PT2										
SOC2										
PT1										
PT2										



# 9.5.2. Vital signs

## Table 67. Change in heart rate from baseline at each visit

Items	Indicator	Experimental group	Control group	Total
Baseline	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Between-group comparison in baseline	Statistics			
	P-value			
Visit 2/Day 7±3	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Between-group comparison in Visit 2/Day $7\pm3$	Statistics			
	P-value			
Change in Visit 2/Day $7 \pm 3$ from baseline	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Pre- and post-treatment comparison of intra-group	Statistical method			
	Statistics			
	P-value			
Comparison of changes between groups pre- and post-treatment	Statistics			
	P-value			
Visit 4/Day 56±7	N (Missing)			
	Mean (SD)			



Items	Indicator	Experimental group	Control group	Total
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Between-group comparison in Visit 4/Day 56 $\pm$ 7	Statistics			
	P-value			
Change in Visit 4/Day 56 $\pm$ 7 from baseline	N (Missing)			
	Mean (SD)			
	Median			
nge in Visit 4/Day 56±7 from baseline - and post-treatment comparison of intra-group nparison of changes between groups pre- and post-treatment it 5/Day 112±7	Q1, Q3			
	Min, Max			
	95%CI			
re- and post-treatment comparison of intra-group Comparison of changes between groups pre- and post-treatment	Statistical method			
	Statistics			
	P-value			
Comparison of changes between groups pre- and post-treatment	Statistics			
	P-value			
Visit 5/Day 112±7	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Between-group comparison in Visit 5/Day $112\pm7$	Statistics			
	P-value			
Change in Visit 5/Day 112 $\pm$ 7 from baseline	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Pre- and post-treatment comparison of intra-group	Statistical method			

Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.



Items	Indicator	Experimental group	Control group	Total
	Statistics			
	P-value			
Comparison of changes between groups pre- and post-treatment	Statistics			
	P-value			
Visit 6/Day 168±7	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
	Statistics			
	P-value			
Change in Visit 6/Day 168 $\pm$ 7 from baseline	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Pre- and post-treatment comparison of intra-group	Statistical method			
- and post-treatment comparison of intra-group	Statistics			
	P-value			
Comparison of changes between groups pre- and post-treatment	Statistics			
	P-value			
Visit 7/Day 224 $\pm$ 7	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Between-group comparison in Visit 7/Day 224 $\pm$ 7	Statistics			
	P-value			
Change in Visit 7/Day 224 $\pm$ 7 from baseline	N (Missing)			
Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	70 / 83			



Items	Indicator	Experimental group	Control group	Total
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Pre- and post-treatment comparison of intra-group	Statistical method			
	Statistics			
	P-value			
een-group comparison in Visit 8/Day 280±7	Statistics			
	P-value			
Visit 8/Day 280±7	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Between-group comparison in Visit 8/Day 280 $\pm$ 7	Statistics			
	P-value			
Change in Visit 8/Day 280 $\pm$ 7 from baseline	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Pre- and post-treatment comparison of intra-group	Statistical method			
	Statistics			
	P-value			
Comparison of changes between groups pre- and post-treatment	Statistics			
	P-value			
Visit 9/Day 364 $\pm$ 7	N (Missing)			
	Mean (SD)			
	Median			

Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.



Items	Indicator	Experimental group	Control group	Total
	Q1, Q3			
	Min, Max			
	95%CI			
Between-group comparison in Visit 9/Day $364 \pm 7$	Statistics			
hange in Visit 9/Day 364 $\pm$ 7 from baseline	P-value			
Change in Visit 9/Day $364 \pm 7$ from baseline	N (Missing)			
Linange in visit 9/Day 504 ⊥ / irom basenne	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	95%CI			
Pre- and post-treatment comparison of intra-group	Statistical method			
	Statistics			
	P-value			
Comparison of changes between groups pre- and post-treatment	Statistics			
	P-value			

Table 68. Change in respiratory rate from baseline at each visit Ibid.

# 9.5.3. Blood routine examination

Table 69. Summary of blood routine examination-Leukocyte count (WBC)

Items	Indicator	Experimental group	Control group	Total
Visit 1/Day 0	Within the normal range n (%)			
	Below the normal range n (%)			
	Higher than the normal range n (%)			
	Total (Missing)			
	Statistics			
	P-value			



Visit 9/Day 364 $\pm$ 7	Within the normal range n (%)
	Below the normal range n (%)
	Higher than the normal range n (%)
	Total (Missing)
	Statistics
	P-value

Table 70. Summary of blood routine examination-Lymphocyte percentage (LY)

Items	Indicator	Experimental group	Control group	Total
Visit 1/Day 0	Within the normal range n (%)			
	Below the normal range n (%)			
	Higher than the normal range n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Visit 9/Day 364±7	Within the normal range n (%)			
	Below the normal range n (%)			
	Higher than the normal range n (%)			
	Total (Missing)			
	Statistics			
	P-value			

Table 71. Shift-table of blood routine examination results before and after treatment-Leukocyte count (WBC)

Group		Day $364 \pm 7$ after treatment						
	Before treatment	Normal	Abnormal but not clinically significant	Abnormal and clinically significant	Not tested	Missing	Total	
xperimental group	Normal							
	Abnormal but not clinically significant							
	Abnormal and clinically significant							
	Not tested							
Hangzhou Zhongmei	huadong Pharmaceutical Co., Ltd.		73 / 83					



	Missing
	Total
Control group	Normal
	Abnormal but not clinically significant
	Abnormal and clinically significant
	Not tested
	Missing
	Total

Table 72. Shift-table of blood routine examination results before and after treatment-Erythrocyte count (RBC) Ibid. Same below.

Table 73. Shift-table of blood routine examination results before and after treatment-Haemoglobin (Hb)

Table 74. Shift-table of blood routine examination results before and after treatment-Platelet count (PLT)

Table 75. Shift-table of blood routine examination results before and after treatment-Lymphocyte percentage (LY)

### 9.5.4. Urine routine examination

Table 76. Shift-table of urine routine examination results before and after treatment-LeukocyteTable 77. Shift-table of urine routine examination results before and after treatment-ErythrocyteTable 78. Shift-table of urine routine examination results before and after treatment-pHTable 79. Shift-table of urine routine examination results before and after treatment-Urine proteinTable 80. Shift-table of urine routine examination results before and after treatment-ColorTable 81. Shift-table of urine routine examination results before and after treatment-Color



## 9.5.5. Serum biochemistry

Table 82. Shift-table of serum biochemistry results before and after treatment-Glutamyl transpeptidase (GT) Table 83. Shift-table of serum biochemistry results before and after treatment-Alanine aminotransferase (ALT) Table 84. Shift-table of serum biochemistry results before and after treatment-Aspartate aminotransferase (AST) Table 85. Shift-table of serum biochemistry results before and after treatment-Lactate dehydrogenase Table 86. Shift-table of serum biochemistry results before and after treatment-Total bilirubin Table 87. Shift-table of serum biochemistry results before and after treatment-Direct bilirubin Table 88. Shift-table of serum biochemistry results before and after treatment-Alkaline phosphatase Table 89. Shift-table of serum biochemistry results before and after treatment-Scr Table 90. Shift-table of serum biochemistry results before and after treatment-Uric acid Table 91. Shift-table of serum biochemistry results before and after treatment-Blood urea nitrogen Table 92. Shift-table of serum biochemistry results before and after treatment-Cystatin C Table 93. Shift-table of serum biochemistry results before and after treatment-Fasting blood glucose Table 94. Shift-table of serum biochemistry results before and after treatment-Total cholesterol Table 95. Shift-table of serum biochemistry results before and after treatment-Triglyceride Table 96. Shift-table of serum biochemistry results before and after treatment-Total protein Table 97. Shift-table of serum biochemistry results before and after treatment-Albumin Table 98. Shift-table of serum biochemistry results before and after treatment-Globulin

## 9.5.6. DNA/antibody test

Table 99. Shift-table of DNA/antibody test results before and after treatment-Blood EBV-DNA Table 100. Shift-table of DNA/antibody test results before and after treatment-IgM Table 101. Shift-table of DNA/antibody test results before and after treatment-IgG

### 9.5.7. Urine test

Table 102. Shift-table of urine test results before and after treatment-24hr urine protein (>3 years old)Table 103. Shift-table of urine test results before and after treatment-Urine protein/creatinine



# 9.5.8. Glomerular filtration rate

Table 104. Shift-table of eGFR results before and after treatment-eGFR

## 9.5.9. Chest X-ray

Table 105. Shift-table of chest X-ray results before and after treatment

# 9.5.10. ECG

Table 106. Shift-table of ECG examination results before and after treatment

## 9.5.11. Concomitant medication and medication adherence

## Table 107. Concomitant medication

Items	Indicator	Experimental group	Control group	Total
Concomitant medication	No n (%)			
	Yes n (%)			
	Total (Missing)			
	Statistics			
	P-value			



## Table 108. Medication adherence

Items	Indicator	Experimental group	Control group	Total
Adherence to tacrolimus capsules/mycophenolate mofetil dispersible tablets (%)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
Adherence to tacrolimus capsules/mycophenolate mofetil dispersible tablets	Excellent (80-120%) n (%)			
	Poor (<80% or >120%) n (%)			
	Total (Missing)			
	Statistics			
	P-value			
Adherence to steroids (%)	N (Missing)			
	Mean (SD)			
	Median			
	Q1, Q3			
	Min, Max			
	Statistics			
	P-value			
Adherence to steroids	Excellent (80-120%) n (%)			
	Poor (<80% or >120%) n (%)			
	Total (Missing)			
	Statistics			
	P-value			



# 10. Attachments

Table 109. List of subjects drop-out (All randomized subjects)

Site Subject code Random number Group Drop-out Trial completion Termination date Treatment discontinuation reason FAS PPS SS Reason for not be included in the PPS

Table 110. List of subjects exclusions (All randomized subjects)

Site Subject code Random number Group Exclusion Trial completion Termination date Treatment discontinuation reason FAS PPS SS Reason for not be included in the PPS

Table 111. List of protocol deviations (All randomize subjects)Note: Analysis based on external file "XX".

Table 112. List of demographic characteristics (FAS)

Site Subject code	Random number	Group Date of birth	Age (years) Gender	Ethnicity	Other ethnicity	Source of disease	Height (cm)	Weight (kg)	BMI (kg/m <sup>2</sup> )
-------------------	---------------	---------------------	--------------------	-----------	-----------------	-------------------	-------------	-------------	--------------------------

Table 113. List of family history and personal history (FAS)

Site Subject Random Group	Family	History of drug	History of	History of pet	Number of Number of	f Birth weight	History of	Feeding	Partial	History of growth and	l Vaccination
code number	history	allergy	surgery	ownership	gestation parturition	n (kg)	dystocia	history	eclipse	development	history



#### Table 114. List of history of other diseases and concomitant medications (FAS)

Site Subject code Random number Group Disease name Start date End date Disease persists or not Drug name Drug dosage form Dosage Frequency Still on medication or not

### Table 115. List of history of nephrotic syndrome (FAS)

Site	Subject code	Random number Group Onset date	Diagnosis date Co	ourse of disease	No. of relapses in the	No. of relapses in the	Time to recurrence	Negative conversion
					past 1 year	past 6 months		time of urine protein

### Table 116. List of treatment history for nephrotic syndrome (FAS)

Site Subject code Random number Group Drug name Drug dosage form Dosage Frequency of medication Start medication date Stop medication date Still on medication or not

Site	Subject code	Random number	Group	Visit	Relapse or not	Serial number	Relapse start date	Relapse end date	Description of relaps

Site	Subject code	Random number	Group	Relapse or not	Relapse start date	Relapse end date	Random date	Analyze date	Endpoint event
------	--------------	---------------	-------	----------------	--------------------	------------------	-------------	--------------	----------------



Table 119	9. List of seconda	ary efficacy indicato	r (first rela	pse after enrollme	nt) situations (FAS/PPS	5)			
Site	Subject code	Random number	Group	Relapse or not	Relapse start date	Relapse end date	Random date	Analyze date	Endpoint event

### Table 120. List of secondary efficacy indicator (6-month relapse-free) situations (FAS/PPS)

Site	Subject code	Random number	Group	Relapse or not	Relapse start date	Relapse end date	Random date	Analyze date	Endpoint event
	5		1	1	1	1		5	1

Table 121. List of blood routine examination results that were normal before treatment and abnormal after treatment (SS)

Site Subject code Random number Group Examination items Visit Baseline result Baseline unit Baseline clinical judgment Visit result Visit unit Visit clinical judgment

Table 122. List of urine routine examination results that were normal before treatment and abnormal after treatment (SS)

Site Subject code Random number Group Examination items Visit Baseline result Baseline unit Baseline clinical judgment Visit result Visit unit Visit clinical judgment

Table 123. List of serum biochemistry results that were normal before treatment and abnormal after treatment (SS)

Site Subject code Random number Group Examination items Visit Baseline result Baseline unit Baseline clinical judgment Visit result Visit unit Visit clinical judgment



#### Table 124. List of urine test results that were normal before treatment and abnormal after treatment (SS)

Site Subject code Random number Group Examination items Visit Baseline result Baseline unit Baseline clinical judgment Visit result Visit unit Visit clinical judgment

### Table 125. List of eGFR results that were normal before treatment and abnormal after treatment (SS)

Site Subje	ct code Random	number Group	Visit E		Baseline clinical judgment	Visit result	Visit clinical judgment
------------	----------------	--------------	---------	--	----------------------------	--------------	-------------------------

### Table 126. List of chest X-ray results that were normal before treatment and abnormal after treatment (SS)

Site Subject code Random number Group Visit Baseline result Baseline clinical judgment Vis	/isit result Visit clinical judgment Description of abnormal
--	--

### Table 127. List of ECG examination results that were normal before treatment and abnormal after treatment (SS)

Site S	Subject code	Random number	Group	Visit	Baseline result	Baseline clinical judgment	Visit result	Visit clinical judgment	Description of abnormal
--------	--------------	---------------	-------	-------	-----------------	----------------------------	--------------	-------------------------	-------------------------



### Table 128. List of AE (SS)

Site Subject code Random number Group AE ID Description of AE Severity Start date Treatment or not AE ended or not End date Treatment Relationships Measures taken on with drug study drug

### Table 129. List of AE-continued (SS)

Site Subject code Random number Group AE ID Description of AE AE outcomes Recovery/cure date Details of sequelae Death date SAE or not Cause withdraw or not

#### Table 130. List of SAE (SS)

Site	Subject code	Random number	Group	SAE ID	Type of SAE	Report date	Description	SAE situations	Death date	Severity Onset Date	SAE	Relationships with
							of SAE				outcomes	drug

#### Table 131. List of SAE-continued (SS)

Site	Subject code	Random number	Group	SAE ID	Type of SAE	Report time	Description	Measures taken on	Reported SAE situation	Details of SAE cccurrence
							of SAE	study drug		and treatment



Table 132. List of concomitant medication (SS)											
Site	Subject code	Random number Group	СМ	China approved	Administration	Single dose	Unit	Frequency	Purpose of	Dosing start date Still in use	Dosing end date
			ID	drug names	route				medication		